TAK-438, Vonoprazan Fumarate CAS 1260141-27-2

TAK-438, Vonoprazan Fumarate CAS 1260141-27-2

CAS No: 1260141-27-2
Molecular Formula:C21H20FN3O6S
Molecular Weight:461.463
EINECS NO:N/A
MDL NO: N/A
Chat Now

Product Details

Product Description:

Product Name: TAK-438 Vonoprazan fumarate CAS NO :1260141-27-2

 

 Synonyms:

1-[5-(2-Fluorophenyl)-1-(3-pyridinylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (2E)-2-butenedioate (1:1);

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine fumarate;

1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine,(E)-4-oxopent-2-enoic acid;

5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate;

  

Chemical & Physical Properties:

Appearance : powder.

Assay : ≥99.0%

Soluble: DMSO > 10 mM

 

Alternate CAS #: Free Base: 881681-00-1

 

Tak-438 (vonoprazan fumarate) is a new oral anti gastric acid drug developed by Takeda pharmaceutical and Otsuka pharmaceutical.

[registration classification] chemical medicine 3.1

[indications] for the treatment of erosive esophagitis, gastric ulcer and duodenal ulcer. On February 28, 2014, Takeda pharmaceutical submitted the new drug application (NDA) of vonoprazan (tak-438) to the Ministry of labor, health and welfare of Japan (MHLW). The submission of the new drug application is based on the good data of phase III clinical trials. Takeda pharmaceutical has carried out several phase III clinical trials in Japan to investigate the efficacy of tak-438 in the eradication of erosive esophagitis, gastric ulcer, duodenal ulcer and Helicobacter pylori. In clinical trials, compared with the current PPIs, warno chemical book razan (tak-438) does not have CYP2C19 metabolism, so it shows better efficacy in clinical trials: it is better than lansoprazole in the treatment of gastric ulcer / duodenal ulcer, reflux esophagitis, root removal of Helicobacter pylori, and has good tolerance and safety. On December 26, 2014, tak-438 (vonoprazanfumarate) was approved for marketing in Japan (trade name: takecab) for the treatment of acid related diseases. Compared with the traditional irreversible proton pump inhibitors (such as omeprazole, esomeprazole, etc.), takecab has the following advantages: ① rapid onset, the first day of administration will achieve the maximum acid inhibition effect; ② oral administration, not affected by gastric acid damage, does not need to be made into enteric solution; ③ to improve the night acid breakthrough phenomenon.

 

 

Applications:Vonoprazan Fumarate is a novel potassium-competitive acid blocker for the treatment of acid-related diseases.

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.


Inquiry

You Might Also Like